Can-Fite BioPharma Reports Positive Phase 2a Results for Pancreatic Cancer Drug Namodenoson

Key Facts

1Can-Fite BioPharma announced that Namodenoson successfully met the primary endpoint in a Phase 2a study for advanced pancreatic cancer.

2The study involved patients with advanced pancreatic ductal adenocarcinoma (PDAC) who had progressed following prior systemic therapies.

3The company's shares are traded on the NYSE American and TASE under the ticker CANF.

Can-Fite BioPharma Ltd. (NYSE American: CANF) has announced successful results from its Phase 2a clinical trial evaluating Namodenoson for advanced pancreatic cancer. The study achieved its primary endpoint, demonstrating the drug's efficacy in patients with advanced pancreatic ductal adenocarcinoma (PDAC). Participants in the trial had previously progressed following other systemic therapies, making this a significant milestone for difficult-to-treat cases. Namodenoson is a small molecule drug designed to target specific receptors in cancer cells while maintaining a favorable safety profile. The company's shares, which trade on both the NYSE American and the Tel Aviv Stock Exchange, are expected to see increased investor interest following this clinical breakthrough. This development marks a critical step forward in Can-Fite's oncology pipeline and its efforts to address unmet medical needs in the cancer treatment landscape.